Pages that link to "Q39495402"

The following pages link to Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial (Q39495402):

Displaying 49 items.

• Medical treatments in the short term management of reflux oesophagitis (Q24234225) (← links)
• Medical treatments in the short term management of reflux oesophagitis (Q24245220) (← links)
• Pharmacology of proton pump inhibitors (Q24634771) (← links)
• Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis (Q31811132) (← links)
• Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs (Q33487903) (← links)
• Safety profile of Lansoprazole: the US clinical trial experience (Q33542545) (← links)
• Heartburn treatment in primary care: randomised, double blind study for 8 weeks (Q33648493) (← links)
• Dyspepsia and heartburn (Q33722910) (← links)
• Digestive system disorders: gastroesophageal reflux disease (Q33727870) (← links)
• Medical therapy. Management of the refractory patient (Q33850189) (← links)
• Economic evaluation of long-term management strategies for erosive oesophagitis (Q33867824) (← links)
• pH, healing rate, and symptom relief in patients with GERD. (Q33898648) (← links)
• Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. (Q33912651) (← links)
• Obstacles to answering doctors' questions about patient care with evidence: qualitative study (Q34010476) (← links)
• Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole (Q34082750) (← links)
• Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. (Q34421486) (← links)
• What is heartburn worth? A cost-utility analysis of management strategies (Q34745082) (← links)
• Acid suppression in gastro-oesophageal reflux disease: Why? How? How much and when? (Q34788219) (← links)
• Esomeprazole tablet vs omeprazole capsule in treating erosive esophagitis (Q35010994) (← links)
• Intragastric maldistribution of a liquid meal in patients with reflux oesophagitis assessed by three dimensional ultrasonography (Q35863344) (← links)
• The role of proton pump inhibitors in gastro-oesophageal reflux disease (Q35660960) (← links)
• Single-isomer drugs: true therapeutic advances (Q35744418) (← links)
• A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials (Q35745058) (← links)
• Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole (Q35841377) (← links)
• Comparative role of omeprazole in the treatment of gastroesophageal reflux disease (Q36803997) (← links)
• Evidence for therapeutic equivalence of lansoprazole 30mg and esomeprazole 40mg in the treatment of erosive oesophagitis (Q39412138) (← links)
• Control of intragastric pH with omeprazole 20 mg, omeprazole 40 mg and lansoprazole 30 mg. (Q39419423) (← links)
• A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis (Q39445913) (← links)
• Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders (Q39453608) (← links)
• Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta‐analysis of long‐term omeprazole trials (Q39455270) (← links)
• Lansoprazole versus omeprazole in active duodenal ulcer. A double-blind, randomized, comparative study (Q39476870) (← links)
• Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders (Q39482244) (← links)
• Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders (Q40394361) (← links)
• Medical management of gastro-oesophageal reflux disease (Q41124471) (← links)
• Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease (Q41445264) (← links)
• Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis (Q41560226) (← links)
• Medical therapy of gastroesophageal reflux and management of esophageal strictures (Q41624139) (← links)
• Trends in the management of gastro-oesophageal reflux disease (Q42124636) (← links)
• Treatment of erosive reflux esophagitis resistant to H2-receptor antagonist therapy. Lansoprazole, a new proton pump inhibitor (Q42281375) (← links)
• Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis (Q42283418) (← links)
• The effect of Helicobacter pylori eradication on gastro-oesophageal reflux (Q44978762) (← links)
• Clinical and fiscal impact of lansoprazole intolerance in veterans with gastro-oesophageal reflux disease (Q45334623) (← links)
• Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects (Q46076164) (← links)
• On demand therapy of reflux oesophagitis--a prospective study of symptoms, patient satisfaction and quality of life. (Q53542943) (← links)
• ▼Lansoprazole - another proton pump inhibitor (Q71812255) (← links)
• Determination of Lansoprazole in pharmaceutical dosage forms by two different spectroscopic methods (Q73509242) (← links)
• Endoscopic Grading of Reflux Oesophagitis: What Observations Correlate with Gastro-Oesophageal Reflux? (Q73664324) (← links)
• Gastric accommodation studied by ultrasonography in patients with reflux esophagitis (Q73797543) (← links)
• Meta-Analyses of Cisapride, Omeprazole and Ranitidine in the Treatment of GORD: Implications for Treating Patient Subgroups (Q80967246) (← links)